Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.68 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927930 | 1.00 | EPHX2 (0.68) | EPHX2PLA2G4APLA2G2ACNR2FAAH | |
| SCHEMBL4795104 | 0.86 | PLA2G4A (0.82) | EPHX2PLA2G4APLA2G2AFAAHKDM4E | |
| SCHEMBL4927236 | 0.86 | PLA2G4A (0.82) | EPHX2PLA2G4APLA2G2AFAAHKDM4E | |
| SCHEMBL16619266 | 0.86 | EPHX2 (0.72) | EPHX2KDM4E | |
| SCHEMBL16619267 | 0.86 | EPHX2 (0.72) | EPHX2KDM4E | |
| SCHEMBL24751538 | 0.85 | EPHX2 (0.73) | EPHX2CNR2FAAH | |
| SCHEMBL8983126 | 0.85 | EPHX2 (0.73) | EPHX2CNR2FAAH | |
| SCHEMBL583238 | 0.85 | EPHX2 (0.73) | EPHX2CNR2FAAH | |
| Methyl Oleate SCHEMBL25202566 | 0.85 | EPHX2 (0.73) | EPHX2CNR2FAAH | |
| SCHEMBL20991368 | 0.85 | EPHX2 (0.73) | EPHX2CNR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
| EP-1937247-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007022443-A2 | SYSTEMIC AND INTRATHECAL EFFECTS OF A NOVEL SERIES OF PHOSPHOLIPASE A2 INHIBITORS ON HYPERALGESIA AND SPINAL PGE2 RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | EPHX2 140/4885PLA2G4A 1/4885PLA2G2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.